Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $6.3 million.

  • Ani Pharmaceuticals' Cash from Financing Activities fell 9781.98% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.2 million, marking a year-over-year decrease of 10396.03%. This contributed to the annual value of $264.9 million for FY2024, which is 29286.61% up from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Cash from Financing Activities stood at $6.3 million, which was down 9781.98% from -$1.7 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Cash from Financing Activities high stood at $291.0 million for Q3 2024, and its period low was -$19.7 million during Q1 2024.
  • Over the past 5 years, Ani Pharmaceuticals' median Cash from Financing Activities value was -$1.5 million (recorded in 2024), while the average stood at $27.2 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 822699.28% in 2021, then plummeted by 224606.3% in 2023.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Cash from Financing Activities stood at $179.4 million in 2021, then plummeted by 100.28% to -$508000.0 in 2022, then tumbled by 2246.06% to -$11.9 million in 2023, then surged by 58.83% to -$4.9 million in 2024, then surged by 229.31% to $6.3 million in 2025.
  • Its last three reported values are $6.3 million in Q3 2025, -$1.7 million for Q2 2025, and -$9.9 million during Q1 2025.